Detail of "148157-34-0"

CAS Number:
148157-34-0
Name:
Interleukin 13 (humanclone A10 precursor reduced) (9CI)
Molecular Weight:
0
Synonyms:
Interleukin13 (human T lymphocyte); Interleukin 13 (human clone 58D9 gene IL-13precursor); Interleukin-13 (human)
Appearance:
lyophilized powder

Display：

storage temp. : ?20°C form : lyophilized powder WGK Germany : 3

Supplier:PEPROTECH [ United States]

320 Integral
320

Tel:800 436 9910

Address:P.O. Box 275 Rocky Hill, NJ 08553

storage temp. : ?20°C form : lyophilized powder

Supplier:BIOSOURCE [ China (Mainland)]

275 Integral
275

Tel:(86-10) 5808-5888

Address:No.7, Rong Chang East Street Long Sheng Industry Park, Building 203 BDA Beijing, 100176

Integral
10

Tel:888 530 0140

Address:USA

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Method of refolding recombinantly prepared human IL-13: Method of refolding recombinantly prepared human IL-13. Culpepper, Janice; Mckenzie, Andrew; Dang, Warren; Zurawski, Gerard (Schering Corporation, USA). U.S. US 5596072 A 21 Jan 1997, 110 pp., Cont.-in-part of U.S. Ser. No. 933,416, abandoned. (English). (United States of America). CODEN: USXXAM. CLASS: ICM: C07K001-00. ICS: C07K014-54. NCL: 530351000. APPLICATION: US 1993-12543 1 Feb 1993. PRIORITY: US 1992-933416 21 Aug 1992. DOCUMENT TYPE: Patent CA Section: 15 (Immunochemistry) Section cross-reference(s): 9 Nucleic acids encoding human IL-13 are isolated and expressed in transgenic Escherichia coli. Methods for refolding a denatured human IL-13 isolated from the transgenic Escherichia coli are described consisting of (1) solubilizing IL-13 protein in 6M guanidine at a concn. of about 2.5 mg/mL; (2) dilg. the guanidine to about 60 mM over a period of hours in the presence of both oxidized and reduced glutathione; and (3) incubating the dild. guanidine soln. for >12 h. Biol. 148157-34-0 and 113-00-8 which are cas registry numbers of substances are two of reagents here. activities of the prepd. human IL-13 are also demonstrated. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compns. for both diagnostic and therapeutic utilities are provided. .